Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Browse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunities​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All Insights Private Market Reports Market Insights Buying and Selling Pre-IPO​ All Reports​Private Market UpdatesForge Investment OutlookStartup News and Trends​Private Market Data and Analytics​Tech IPO Calendar for 2025Magnificent 7Private Market Explained​Buying Pre-IPO Shares​Selling Pre-IPO SharesGlossaryVideosFAQsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Secondary Marketplace / Trade Private Companies / Buy and Sell Lycia Therapeutics Stock
Lycia Therapeutics

Lycia Therapeutics Stock

$313.67MM
Series C Valuation, May 2024
Register To Buy and Sell Private Company Shares
For more details on private stock price information, financing and valuation for Lycia Therapeutics, register or login.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Sign in

Lycia Therapeutics Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Lycia Therapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
05/13/2024 Series C $106.6MM $xx.xx $313.67MM Alexandria Venture Investments, Blue Owl Healthcare Opportunities, Eli Lilly & Company, Franklin Templeton, Invus, Janus Henderson Investors, Marshall Wace, Redmile Group, Rtw Investments, Venrock Healthcare Capital Partners
Price per Share
$xx.xx
Shares Outstanding
52,211,394
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
3
Key Investors
Alexandria Venture Investments, Blue Owl Healthcare Opportunities, Eli Lilly & Company, Franklin Templeton, Invus, Janus Henderson Investors, Marshall Wace, Redmile Group, Rtw Investments, Venrock Healthcare Capital Partners
09/09/2021 Series B $71.32MM $xx.xx $195.08MM Alexandria Venture Investments, Cowen Healthcare Investments, Eli Lilly & Company, Invus, Redmile Group, Rtw Investments, Versant Ventures
Price per Share
$xx.xx
Shares Outstanding
39,597,569
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
3
Key Investors
Alexandria Venture Investments, Cowen Healthcare Investments, Eli Lilly & Company, Invus, Redmile Group, Rtw Investments, Versant Ventures
06/09/2020 Series A $25.39MM $xx.xx $63.48MM Versant Ventures
Price per Share
$xx.xx
Shares Outstanding
25,390,410
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
3
Key Investors
Versant Ventures
Company Details
Lycia Therapeutics is a biotechnology company and the developer of a treatment technology, Lysosomal Targeting Chimera (LYTAC), that aims to degrade extracellular proteins with the goal of treating conditions including cancer, inflammation, and autoimmune disorders. The company has a mission to uncover use cases for the LYTAC platform using extracellular protein degradation designed to target soluble and membrane-bound proteins. Lycia Therapeutics was founded in 2019 by Dr. Carolyn Bertozzi and is headquartered in San Francisco, CA.
Founded
2019
Headquarters
South San Francisco, CA, United States
Post-Money Valuation 3
$313.67MM
Total Funding
$406.62MM
LFR Price per Share
$xx.xx
Last Funding Share Class
Series C

Lycia Therapeutics Stock FAQs

To buy and sell Lycia Therapeutics stock
Can you buy Lycia Therapeutics stock?
As Lycia Therapeutics is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Lycia Therapeutics, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
How to buy Lycia Therapeutics stock?

To invest in a private company like Lycia Therapeutics through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
Can you sell Lycia Therapeutics stock?
Yes, you may sell the Lycia Therapeutics stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
How to sell Lycia Therapeutics stock?

If you hold private company shares of Lycia Therapeutics – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Lycia Therapeutics on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
To learn more about Lycia Therapeutics stock
Is Lycia Therapeutics a public company?
No, Lycia Therapeutics is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
What is Lycia Therapeutics’ stock price?
Lycia Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Lycia Therapeutics private market stock price with Forge Data.
What is Lycia Therapeutics’ stock ticker symbol?
Lycia Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Lycia Therapeutics Investors Also Invested in These Private Companies

Venrock Healthcare Capital Partners
Blue Owl Healthcare Opportunities

Leadership & Board

Leadership

Aetna Wun Trombley Ph.D
President & Chief Executive Officer
Steve Staben Ph.D
Chief Scientific Officer
Sofia Touami Ph.D
Chief Business Officer
Jian Cao Ph.D
Vice President of Chemistry, Manufacturing and Controls (CMC)
Winsome Chung
Vice President of Finance
Matthew Holdren Ph.D
Vice President, Head of Nonclinical Development
Darrin Lindhout Ph.D
Executive Director, Head of Biologics
Sarah McWhirter Ph.D
Vice President, Head of Biology
Larry Rozsnyai Ph.D
Vice President of Intellectual Property
Nadia Tchao MD
Executive Director, Head of Translational Medicine/Early Development

Board

Andrew Gottesdiener MD
Venrock
Clare Ozawa Ph.D
Versant Ventures
Ming Fang
Redmile Group
Thomas Woiwode Ph.D
Versant Ventures
Timothy Anderson
Cowen Healthcare Investments

Lycia Therapeutics News and Media Highlights

Lycia Therapeutics Lands $106M for Protein Degraders That Treat Autoimmune & Inflammatory Diseases

In a series C funding round led by Venrock Healthcare Capital Partners, Lycia Therapeutics raised $106 million.
Browse Insights
Other Companies Like Lycia Therapeutics in the BioTech & Pharma Sector
Sector: Healthcare
Subsector: BioTech & Pharma
Last Funding Round
Company Forge Price Forge Price Change 5 Last Closed Trade Share Class Post-Money Valuation Price per Share Amount Raised
Affinia TherapeuticsAffinia Therapeutics----$xx.xxSeries B$365.7MM$xx.xx$110MM
Altos LabsAltos Labs----$xx.xxSeries C$6.33B$xx.xx$1.5B
Colossal BiosciencesColossal Biosciences----$xx.xxSeries C$10.2B$xx.xx$200MM
EgenesisEgenesis----$xx.xxSeries D$332.59MM$xx.xx$90.96MM
Eikon TherapeuticsEikon Therapeutics----$xx.xxSeries D$1.45B$xx.xx$400MM
Isomorphic LabsIsomorphic Labs----$xx.xx--------
Kailera TherapeuticsKailera Therapeutics----$xx.xxSeries A-2 NV$580.71MM$xx.xx$7.09MM
LoyalLoyal----$xx.xxSeries B-5$428.44MM$xx.xx$17.49MM
Mammoth BiosciencesMammoth Biosciences----$xx.xxSeries D-2$1.35B$xx.xx$107.74MM
OriginOrigin----$xx.xx--------

Updated on: Feb 13, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.